G. Fyfe
Impact in
Papers in
- Co-authors
- Richard I. Fisher (3 shared papers)Mario Sznol (2 shared papers)David Parkinson (1 shared paper)Arthur C. Louie (1 shared paper)S A Rosenberg (1 shared paper)Steven A. Rosenberg (1 shared paper)Robert Walker (3 shared papers)Michael A. Polis (3 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)The Journal of Infectious Diseases (3 papers)The Journal of Immunology (1 paper)The Journal of Pediatrics (1 paper)New England Journal of Medicine (1 paper)
- Partner nations
- United StatesJapanAustralia
In The Last Decade
G. Fyfe
19 papers receiving 2.6k citations
G. Fyfe's Hit Papers
Peers
Comparison fields: 5 of 89
- Virology 518
- Oncology 1.2k
- Immunology 839
- Cancer Research 483
- Pulmonary and Respiratory Medicine 1.0k
Countries citing papers authored by G. Fyfe
This map shows the geographic impact of G. Fyfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Fyfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Fyfe more than expected).
Fields of papers citing papers by G. Fyfe
This network shows the impact of papers produced by G. Fyfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Fyfe. The network helps show where G. Fyfe may publish in the future.
Co-authors
The 25 scholars most cited alongside G. Fyfe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Hit paper breakdown → | 1995 | 1041 |
| 2 | Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. | 2000 | 352 |
| 3 | 1996 | 320 | |
| 4 | 2001 | 299 | |
| 5 | 1997 | 139 | |
| 6 | 1999 | 112 | |
| 7 | 1995 | 73 | |
| 8 | High-dose aldesleukin in renal cell carcinoma: long-term survival update. | 1997 | 72 |
| 9 | 1998 | 69 | |
| 10 | 1985 | 51 | |
| 11 | 2003 | 45 | |
| 12 | 1987 | 42 | |
| 13 | 2004 | 31 | |
| 14 | 2004 | 18 | |
| 15 | 2004 | 16 | |
| 16 | 2010 | 13 | |
| 17 | 2003 | 11 | |
| 18 | 2004 | 5 | |
| 19 | 2001 | 4 |
About G. Fyfe
G. Fyfe is a scholar working on Oncology, Virology, Pulmonary and Respiratory Medicine, Infectious Diseases and Surgery, having authored 19 papers that have together received 2.7k indexed citations. Recurring topics across this work include HIV Research and Treatment (6 papers), Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), HIV/AIDS Research and Interventions (3 papers), Bladder and Urothelial Cancer Treatments (3 papers), HIV/AIDS drug development and treatment (3 papers) and Renal cell carcinoma treatment (3 papers). The work is most often cited by research in Virology (518 citations), Oncology (1.2k citations), Immunology (839 citations), Cancer Research (483 citations) and Pulmonary and Respiratory Medicine (1.0k citations). G. Fyfe has collaborated with scholars based in United States, Japan and Australia. Frequent co-authors include Richard I. Fisher, Mario Sznol, David Parkinson, Arthur C. Louie, S A Rosenberg, Steven A. Rosenberg, Robert Walker, Michael A. Polis, Joseph A. Kovacs and Judith Falloon. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Infectious Diseases, The Journal of Immunology, The Journal of Pediatrics and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.